A Randomized, Open-Label, 2-Period, Crossover Study to Assess the Bioequivalence of One 150 mg Risedronate [risedronic acid] Tablet Versus Two 75 mg Risedronate Tablets Administered as a Single Oral Dose in Healthy Male and Female Subjects

Trial Profile

A Randomized, Open-Label, 2-Period, Crossover Study to Assess the Bioequivalence of One 150 mg Risedronate [risedronic acid] Tablet Versus Two 75 mg Risedronate Tablets Administered as a Single Oral Dose in Healthy Male and Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2013

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Osteoporosis
  • Focus Pharmacokinetics
  • Sponsors Procter & Gamble
  • Most Recent Events

    • 24 Mar 2010 Warner-Chilcott added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
    • 14 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top